The first three years of buprenorphine in the united states: Experience to date and future directions

Journal of Addiction Medicine

Volumn 1, Issue 2, 2007, Pages 62-67

  Fiellin, David A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38149016864     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3180473c11     Document Type: Review

References (18)

1. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. A potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35:501-516.
2. Lepay D, Clark HW. Dear Colleague Letter on Medical Maintenance. Food and Drug Administration Center for Substance Abuse Treatment. March 30, 2000.
3. Fiellin DA, O'Connor PG. New Federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137: 688-692.
4. Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis. 2006;43 (Suppl 4):S191-S196.
5. Sullivan LE, Tetrault J, Bangalore D, et al. Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abuse. 2006;27: 13-18.
6. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/ naloxone and HIV clinical care. Clin Infect Dis. 2006;43(Suppl 4):S184-S190.
7. Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25: 91-103.
8. Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in office- based treatment of opioid dependence [6]. New Engl J Med. 2005;353: 1863-1865.
9. Anonymous. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2006. DHHS Publication No. (SMA) 06-4143.
10. Anonymous. Opioid drugs in maintenance and detoxification treatment of opiate addiction: addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. In: Substance Abuse and Mental Health Services Administration (SAMHSA) DoHaHS. Vol 68. Federal Register; 2003.
11. Clark HW. Dear Colleague Letter. Center for Substance Abuse Treatment. April 3, 2006.
12. Anonymous. States' perspectives on buprenorphine and office-based medication-assisted opioid dependency treatment. Available at: http:// www.nasadad.org/resource.php?base-id-83. Accessed March 15, 2007.
13. Gelber S. The Reimbursement Environment for Buprenorphine. Berkely, CA: The Avisa Group; 2004.
14. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict. 2004;13 (Suppl. 1):S17-S28.
15. Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43 (Suppl 4):S197-S215.
16. Lintzeris N, Ritter A, Panjari M, et al. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict. 2004;13 (Suppl 1):S29-S41.
17. Schackman BR, Merrill JO, McCarty D, et al. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43 (Suppl 4):S247-S253.
18. Anonymous. Evaluation of the Buprenorphine Waiver Program Buprenorphine Reimbursement and Availability Tracking Study. Berkely, CA: The Avisa Group; 2005.